Artwork

Content provided by DSI, Meranda Parascandola, and Ed Narke. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DSI, Meranda Parascandola, and Ed Narke or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

009 Recipes to Build Towards Your NDA/BLA - Ed Narke, Brian Lihou and Meranda Parascandola

50:50
 
Share
 

Manage episode 277251876 series 2821798
Content provided by DSI, Meranda Parascandola, and Ed Narke. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DSI, Meranda Parascandola, and Ed Narke or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

What We Covered

  • 00:44 – Ed, Brian and Meranda join the show to share their experiences in all phases of the pharmaceutical development industry
  • 5:12 – The process of filing an Investigational New Drug (IND) and a New Drug Application (NDA)
  • 18:54 – What it means to have ‘rest-of-world awareness’ as you author an NDA
  • 22:37 – Ed, Brian and Meranda speak to the importance of storyboards and telling a story from the right perspective
  • 28:55 – Ed, Brian and Meranda break down the detailed development process, including the work that Design Space InPharmatics does
  • 39:28 – The document review process, timelines for submissions and tracking projects
  • 49:00 – Ed, Brian and Meranda conclude the podcast and thank the audience for listening

Tweetable Quotes

“Filing an IND is important to get a trial started. And folks start clinical trials for a variety of reasons.” (05:43) (Ed)

“Out of academia we see a lot of this very little information filed into an IND, and then very little information generated up to the point where you get to a Phase Two or Three where you see efficacy data and then suddenly you have to file an NDA.”

“It’s hard to become an expert. There’s no real training. I think a lot of it is just experience. It’s going into meetings with FDA when you don’t have all the data.”

“Make sure it looks good, because it does reflect on the actual data and content in there, just like anything in life.”

“As the author goes through the process with the client, there’s still another piece. And that’s the publishing group.”

“One way to alleviate that [stress] is to be able to give an update on any given subject or any given section at any given time.”

Relevant Links

Design Space InPharmatics - LinkedIn

Design Space InPharmatics - Twitter

Edward Narke on LinkedIn

Brian Lihou on LinkedIn

Meranda Parascandola on LinkedIn

  continue reading

27 episodes

Artwork
iconShare
 
Manage episode 277251876 series 2821798
Content provided by DSI, Meranda Parascandola, and Ed Narke. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DSI, Meranda Parascandola, and Ed Narke or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

What We Covered

  • 00:44 – Ed, Brian and Meranda join the show to share their experiences in all phases of the pharmaceutical development industry
  • 5:12 – The process of filing an Investigational New Drug (IND) and a New Drug Application (NDA)
  • 18:54 – What it means to have ‘rest-of-world awareness’ as you author an NDA
  • 22:37 – Ed, Brian and Meranda speak to the importance of storyboards and telling a story from the right perspective
  • 28:55 – Ed, Brian and Meranda break down the detailed development process, including the work that Design Space InPharmatics does
  • 39:28 – The document review process, timelines for submissions and tracking projects
  • 49:00 – Ed, Brian and Meranda conclude the podcast and thank the audience for listening

Tweetable Quotes

“Filing an IND is important to get a trial started. And folks start clinical trials for a variety of reasons.” (05:43) (Ed)

“Out of academia we see a lot of this very little information filed into an IND, and then very little information generated up to the point where you get to a Phase Two or Three where you see efficacy data and then suddenly you have to file an NDA.”

“It’s hard to become an expert. There’s no real training. I think a lot of it is just experience. It’s going into meetings with FDA when you don’t have all the data.”

“Make sure it looks good, because it does reflect on the actual data and content in there, just like anything in life.”

“As the author goes through the process with the client, there’s still another piece. And that’s the publishing group.”

“One way to alleviate that [stress] is to be able to give an update on any given subject or any given section at any given time.”

Relevant Links

Design Space InPharmatics - LinkedIn

Design Space InPharmatics - Twitter

Edward Narke on LinkedIn

Brian Lihou on LinkedIn

Meranda Parascandola on LinkedIn

  continue reading

27 episodes

ทุกตอน

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide